-
Prof. Lin Zhang: Precision Surgery Empowers Y-90 Therapy
The field of cancer treatment has made substantial progress, entering an era of multi-faceted, comprehensive approaches. With the government’s focus on major diseases, traditional cancer treatments like surgery, interventional therapy, radiotherapy, and chemotherapy have evolved into multidisciplinary approaches. Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) is now emerging as a key treatment option for liver…
-
SITC 2024丨First-Line Dostarlimab Plus Chemotherapy Shows Overall Survival Advantage in Advanced NSCLC
The PERLA trial results demonstrated that Dostarlimab plus chemotherapy achieved better overall survival (OS) compared to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC), with a median OS of 20.2 months vs. 15.9 months.
-
WCLC 2024丨Dr. Mark G. Kris: New Standards in Treating Resectable NSCLC—Perioperative vs. Neoadjuvant Therapy?
The treatment of resectable non-small cell lung cancer (NSCLC) continues to evolve, with debates focusing on whether patients should receive adjuvant immunotherapy following successful neoadjuvant immunotherapy and surgery. This topic was a highlight of discussions at the 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer…
-
Dr. Jin Yang: Advancing Quality Control in Breast Cancer Care—Insights into National Performance Indicators and Challenges
Editorial Note: Quality control has become an increasingly critical focus in breast cancer diagnosis and treatment. As China enhances its cancer prevention and control framework, the standardization of breast cancer care is receiving growing attention. At the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Dr. Jin Yang from The First Affiliated…
-
Dr. Fei Ma: Pioneering Quality Control to Elevate Breast Cancer Care—A Comprehensive Overview of Progress and Future Directions
Breast cancer poses a significant global challenge to women’s health. In China, unprecedented efforts are being made to advance standardized diagnosis and quality control in breast cancer care. During the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Oncology Frontier interviewed the conference chair, Dr. Fei Ma from the Cancer Hospital Chinese…
-
CCHIO 2024丨Dr. Jin Zhang: Achievements of CBCS Over 38 Years and Advances in HR+ Breast Cancer Precision Diagnosis and Treatment
From November 15 to 17, 2024, the Chinese Congress on Holistic Integrative Oncology (CCHIO)(CCHIO) was held in Xi’an under the theme “Winning in Integration: Tumor Prevention and Treatment.” In the breast cancer domain, the conference integrated the latest global advancements in diagnosis, treatment, and research. At the event, Oncology Frontier interviewed Dr. Jin Zhang, Chair…
-
Dr. Qiang Wei: International and Domestic Experts Discuss Annual Advances in Urological Oncology; Demonstrating MDT Applications to Drive Standardization in China | 8th West China Uro-Oncology Tianfu Academic Conference
From November 4–10, 2024, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Urological and Male Reproductive Oncology Annual Conference of the Sichuan Anti-Cancer Association were successfully held in Chengdu. This event shared the latest domestic and international advancements in clinical data, research findings, complex case discussions, and cutting-edge diagnostics and treatment. Following…
-
Dr. Quchang Ouyang: A New Perspective on Breast Cancer Diagnosis and Treatment—Innovative Applications of PROs in Quality Control
With advancements in breast cancer diagnosis and treatment, alongside the increasing diversity of patient needs, a comprehensive evaluation of treatment outcomes and improved quality of life have become focal points in this field. In recent years, Patient-Reported Outcomes (PROs) have emerged as a novel evaluation tool, playing an increasingly important role in breast cancer care.…
Connecting Medical Expertise through Media